AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9119100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous albumin (10 g 20%, 50 ml) infusion before oocyte pick-up
Number of subjects: 55
Study 9119100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 55
Study 1949135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular sulfadoxine-pyrimethamine (25 mg/kg plus 1.25 mg/kg in a single dose)
Number of subjects: 102
Study 1949135 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular quinine (10 mg/kg 8-hourly for at least 3 days followed by oral quinine to complete 7 days)
Number of subjects: 102
Study 31694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (ZS) 30 mg/day
Number of subjects: 48
Study 31694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (ZS) 15 mg/day
Number of subjects: 48
Study 31694220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (ZS)
Number of subjects: 48
Study 28756579 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational multidisciplinary antibiotic team (intervention group)
Number of subjects: 17
Study 28756579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no operational multidisciplinary antibiotic team)
Number of subjects: 17
Study 26501204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine (10 mg)
Number of subjects: 60
Study 26501204 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo + oral moxifloxacin (400 mg; positive control)
Number of subjects: 60
Study 26501204 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 60
Study 25335480 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diet quality (measured by Healthy Eating Index 2005)
Number of subjects: 636
Study 25335480 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diet quality (among women with waist circumference of 88 cm or less and no history of diabetes)
Number of subjects: 636
Study 21076160 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pleomorphism (PL) in M-VT episodes
Number of subjects: 315
Study 21076160 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple morphologies (MM) in M-VT episodes
Number of subjects: 315
Study 21076160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in patients with pleomorphism (PL)
Number of subjects: 315
Study 21076160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in patients with multiple morphologies (MM)
Number of subjects: 315
Study 21076160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in female patients
Number of subjects: 315
Study 21076160 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of mortality
Number of subjects: 315
Study 18483853 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin (PCb) every 3 weeks
Number of subjects: 416
Study 18483853 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and gemcitabine (GDoc) every 3 weeks
Number of subjects: 416
Study 18483853 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (Pw)
Number of subjects: 416
Study 18483853 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and gemcitabine (GDoc)
Number of subjects: 416
Study 18483853 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (PCb)
Number of subjects: 416
Study 18483853 — intervention group
Group type: COMPARATOR
Intervention: Quality of life (QoL) assessment
Number of subjects: 416
Study 18483853 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis
Number of subjects: 416
Study 17455445 — intervention group
Group type: EXPERIMENTAL
Intervention: SM2: application of a methyl methacrylate‐based bonding agent (Vitacol)
Number of subjects: 24
Study 17455445 — intervention group
Group type: EXPERIMENTAL
Intervention: SM3: air abrasion with 30‐microm silicone oxide plus silane
Number of subjects: 24
Study 17455445 — intervention group
Group type: EXPERIMENTAL
Intervention: SM4: SM3 plus SM2
Number of subjects: 24
Study 17455445 — intervention group
Group type: COMPARATOR
Intervention: SM1: No surface treatment (control)
Number of subjects: 24
Study 14683738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 8986
Study 14683738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8986
Study 11772792 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rewarm (n = 65)
Number of subjects: 165
Study 11772792 — intervention group
Group type: COMPARATOR
Intervention: Conventional warming (Control; n = 100)
Number of subjects: 165
Study 9468065 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure at 1,000 m and 2,500 m
Number of subjects: 23
Study 9468065 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Number of subjects: 23
Study 7893035 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/alfentanil
Number of subjects: 50
Study 7893035 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil
Number of subjects: 50
Study 7893035 — intervention group
Group type: COMPARATOR
Intervention: Preincision hemodynamic variables
Number of subjects: 50
Study 2575480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 86
Study 2575480 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 86
Study 82355 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treatment
Number of subjects: 75
Study 82355 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + vitamin A treatment
Number of subjects: 75
Study 82355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A treatment
Number of subjects: 75
Study 82355 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 75
Study 31490370 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity exercise training
Number of subjects: 20
Study 28535400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervista HPV HR test
Number of subjects: 3280
Study 28535400 — intervention group
Group type: COMPARATOR
Intervention: Luminex XMAP technology
Number of subjects: 3280
Study 26065499 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 123
Study 26065499 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 123
Study 23084706 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 58
Study 23084706 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 58
Study 21243736 — intervention group
Group type: EXPERIMENTAL
Intervention: VeraTran (verapamil/trandolapril 180 mg/2 mg daily)
Number of subjects: 281
Study 21243736 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril (2 mg daily)
Number of subjects: 281
Study 21243736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients regressing to normoalbuminuria
Number of subjects: 281
Study 21243736 — intervention group
Group type: COMPARATOR
Intervention: Patients not regressing to normoalbuminuria
Number of subjects: 281
Study 19653080 — intervention group
Group type: EXPERIMENTAL
Intervention: Laplacian approximation (LAPLACE)
Number of subjects: 551
Study 19653080 — intervention group
Group type: EXPERIMENTAL
Intervention: GQ 9 points
Number of subjects: 551
Study 19653080 — intervention group
Group type: COMPARATOR
Intervention: Methods implemented in SAS
Number of subjects: 551
Study 16932987 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered teen mothers (African-Americans)
Number of subjects: 751
Study 16932987 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered teen mothers (Latinas)
Number of subjects: 751
Study 15078378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal tramadol (2 mg.kg(‐1) after surgery)
Number of subjects: 134
Study 15078378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal tramadol (2 mg.kg(‐1) before incision)
Number of subjects: 134
Study 15078378 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol (2 mg.kg(‐1) after surgery)
Number of subjects: 134
Study 15078378 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol (2 mg.kg(‐1) after anaesthesia induction)
Number of subjects: 134
Study 15078378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal tramadol (both preoperative and postoperative)
Number of subjects: 134
Study 10764900 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom limb pain (PLP) patients
Number of subjects: 11
Study 10764900 — intervention group
Group type: COMPARATOR
Intervention: Painfree amputees
Number of subjects: 11
Study 9267140 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral etoposide (25 mg) with concurrent radiation therapy (ERT group)
Number of subjects: 41
Study 9267140 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (RT group)
Number of subjects: 41
Study 8454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and infant food avoidance
Number of subjects: 288
Study 3530128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 203
Study 3530128 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 203
Study 29433537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-phone-based intervention (24 voice messages sent every 2 weeks)
Number of subjects: 640
Study 29433537 — intervention group
Group type: COMPARATOR
Intervention: Existing standard of care (control group)
Number of subjects: 640
Study 26266659 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln plus ED (total oral intake of 8862 mg Gln/day)
Number of subjects: 30
Study 26266659 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln (oral intake of 8910 mg Gln/day)
Number of subjects: 30
Study 26266659 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 26266659 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln plus ED
Number of subjects: 30
Study 25622524 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (semi-standardised including joint and soft tissue mobilisation, stretching, muscle retraining, functional retraining, and education)
Number of subjects: 20
Study 25622524 — intervention group
Group type: COMPARATOR
Intervention: Health education (control intervention with the same frequency and duration as the physiotherapy intervention)
Number of subjects: 20
Study 23044768 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata extract (HMPL-004) 1,200 mg daily
Number of subjects: 224
Study 23044768 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata extract (HMPL-004) 1,800 mg daily
Number of subjects: 224
Study 23044768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 21039208 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (AL-TENS)
Number of subjects: 43
Study 21039208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AL-TENS)
Number of subjects: 43
Study 18389732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Plus
Number of subjects: 90
Study 18389732 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 90
Study 18389732 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt
Number of subjects: 90
Study 18389732 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 16548929 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1071
Study 16548929 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 1071
Study 16548929 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or psychosocial interventions)
Number of subjects: 1071
Study 12648032 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0
Study 12648032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10725619 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (150 mg/m²) administered 15-30 min prior to each radiation session
Number of subjects: 26
Study 10725619 — intervention group
Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 26
Study 9330416 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 15
Study 9330416 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intermittent Mandatory Ventilation (IMV)
Number of subjects: 15
Study 9330416 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV) with late triggering (200-300 msec)
Number of subjects: 15
Study 9330416 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented breaths
Number of subjects: 15
Study 1526081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin alone (400 mg)
Number of subjects: 12
Study 1526081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin after ranitidine (50 mg IV)
Number of subjects: 12
Study 1526081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin after pentagastrin (2 micrograms/kg SC)
Number of subjects: 12
Study 1526081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin after combined ranitidine and pentagastrin treatment
Number of subjects: 12
Study 3516951 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (4500 rad to the breast/chest wall, and internal mammary, axillary and supraclavicular lymph nodes)
Number of subjects: 960
Study 3516951 — intervention group
Group type: COMPARATOR
Intervention: Surgical controls (modified radical mastectomy alone)
Number of subjects: 960
Study 30901130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 97
Study 30901130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg ketamine
Number of subjects: 97
Study 30901130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-monsoon CO2 concentrations
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer CO2 concentrations
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter CO2 concentrations
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: CH4 concentrations in all seasons
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-monsoon N2O concentrations
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer N2O concentrations
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter N2O concentrations
Number of subjects: 0
Study 28233149 — intervention group
Group type: EXPERIMENTAL
Intervention: Average concentrations of gases in commercial areas
Number of subjects: 0
Study 26488927 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline catheters
Number of subjects: 211
Study 26488927 — intervention group
Group type: COMPARATOR
Intervention: Standard-length PVCs
Number of subjects: 211
Study 24090395 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month scale and polish
Number of subjects: 369
Study 24090395 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month scale and polish
Number of subjects: 369
Study 24090395 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month scale and polish
Number of subjects: 369
Study 21672319 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 100
Study 21672319 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 100
Study 19576339 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 201
Study 19576339 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 201
Study 17356531 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational/behavioral intervention (small group seminars)
Number of subjects: 115
Study 17356531 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention (control group)
Number of subjects: 115
Study 15297045 — intervention group
Group type: EXPERIMENTAL
Intervention: inactivated-gp120-depleted HIV-1 Immunogen plus antiretrovirals (ARTs)
Number of subjects: 243
Study 15297045 — intervention group
Group type: EXPERIMENTAL
Intervention: inactivated-gp120-depleted HIV-1 Immunogen
Number of subjects: 243
Study 15297045 — intervention group
Group type: COMPARATOR
Intervention: antiretroviral therapy alone
Number of subjects: 243
Study 12107551 — intervention group
Group type: EXPERIMENTAL
Intervention: IST-622 (280 or 525 mg/m² once daily for five consecutive days)
Number of subjects: 18
Study 9730857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E administration (500 i.u. twice daily for 4 weeks)
Number of subjects: 7
Study 9730857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E administration
Number of subjects: 7
Study 8014585 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d) + low cholesterol diet (mean 246 mg/day)
Number of subjects: 12
Study 8014585 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d) + high cholesterol diet (mean 1071 mg/day)
Number of subjects: 12
Study 8014585 — intervention group
Group type: COMPARATOR
Intervention: low cholesterol diet alone
Number of subjects: 12
Study 8014585 — intervention group
Group type: COMPARATOR
Intervention: high cholesterol diet alone
Number of subjects: 12
Study 2900132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg, increased to 50 mg if necessary)
Number of subjects: 8
Study 2900132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31673086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) using Inbody 230 multifrequency analyzer
Number of subjects: 170
Study 31019123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg/day
Number of subjects: 45
Study 28545498 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOOT program (6 weeks of one-to-one scooter training by an experienced occupational therapist, training once or twice per week)
Number of subjects: 40
Study 28545498 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOOT program
Number of subjects: 40
Study 26322280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 mg/kg
Number of subjects: 120
Study 26322280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 120
Study 26322280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine-tramadol
Number of subjects: 120
Study 26322280 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 23434387 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated monovalent H1N1pdm09 vaccine
Number of subjects: 703
Study 23434387 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated trivalent 2009-10 seasonal influenza vaccine
Number of subjects: 703
Study 23434387 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 703
Study 22097202 — intervention group
Group type: EXPERIMENTAL
Intervention: Biantong Huangqi Ointment (BHO), one dose daily during remission phase for 1 month
Number of subjects: 84
Study 22097202 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM) alone during onset phase
Number of subjects: 84
Study 22097202 — intervention group
Group type: EXPERIMENTAL
Intervention: Biantong Huangqi Ointment (BHO)
Number of subjects: 84
Study 19797985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg/day
Number of subjects: 218
Study 19797985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 218
Study 19797985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 218
Study 19797985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 19797985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (all doses)
Number of subjects: 218
Study 17132483 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal closure
Number of subjects: 43
Study 17132483 — intervention group
Group type: COMPARATOR
Intervention: Vertical closure
Number of subjects: 43
Study 15229392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 840
Study 15229392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study 11771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopic‐guided LMA insertion
Number of subjects: 149
Study 11771605 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion technique
Number of subjects: 149
Study 9249998 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201
Number of subjects: 18
Study 9249998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study 8518768 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest exercise intervention
Number of subjects: 36
Study 8518768 — intervention group
Group type: COMPARATOR
Intervention: Control group (discussion controls)
Number of subjects: 36
Study 3224601 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 30
Study 3224601 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 30
Study 3224601 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formula meal
Number of subjects: 30
Study 3224601 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast meal
Number of subjects: 30
Study 29395476 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional responsiveness (RIAS composite of codes)
Number of subjects: 84
Study 29395476 — intervention group
Group type: EXPERIMENTAL
Intervention: Question asking (RIAS coded communication)
Number of subjects: 84
Study 29395476 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical counseling (RIAS coded communication)
Number of subjects: 84
Study 29395476 — intervention group
Group type: EXPERIMENTAL
Intervention: RIAS-coded communication variables
Number of subjects: 84
Study 28490512 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight z score at 3 months preconception (zwt-3 mo)
Number of subjects: 670
Study 28490512 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight z score at 3 months postconception (zwt+7 mo)
Number of subjects: 670